IMAGING CHARACTERISTICS OF 3.0-T MRI IN PROSTATE CANCER

Đình Minh Nguyễn, Ngọc Dương Vũ

Main Article Content

Abstract

Objective: To study the imaging features of 3.0-T MRI in prostate cancer (PCa). Methods: 25 patients (Pts) underwent prostate 3.0-T MRI from 03/2023 to 10/2023, with post-biopsy/surgical pathology confirming PCa. Results: The mean age of Pts was 72.6 ± 6.6 (range 59 to 82 years). The total number of detected lesions on 3.0-T MRI was 89. On T2-weighted imaging (T2W), all 44 (100%) lesions in the transition zone and 42 (93.3%) lesions in the peripheral zone showed hypointensity (p = 0.3), however, 64 (72%) lesions were homogenous, and 23% were heterogeneous (p < 0.05). On diffusion-weighted imaging (DWI), the restricted diffusion in the peripheral and transition zones indicated PCa in 38 (84.4%) and 37 (84.1%) lesions, respectively (p = 1). After dynamic contrast-enhanced (DCE) imaging, the early enhancement rate in the peripheral zone was 42.2% lesions, higher than in the transition zone at 15.9% (p < 0.05). Invasion signs included capsule interruption in 14 Pts (56%), bladder wall invasion in 12 Pts (48%), seminal vesicle invasion in 18 Pts (72%). Pelvis node extension was observed in 13 Pts (52%), and bone in 3 Pts (12%). The distribution according to Prostate Imaging-Reporting and Data System (PI-RADS) v.2.0 scores were PIRADs I and II (0%), PIRADs III in 4 Pts (16%), PIRADs IV in 9 Pts (36%), and PIRADs V in 12 Pts (48%). Conclusion: The imaging features on 3.0-T MRI are reliable in diagnosing prostate cancer.

Article Details

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
2. Nguyễn Thị Nhân, Nguyễn Thanh Hải, Lê Hồng Chiến, Ngô Văn Đoan, Vũ Thị Hậu. Giá trị bước đầu của cộng hưởng từ đa thông số theo phân loại PI-RADSv2.1 trong phát hiện ung thư tuyến tiền liệt có ý nghĩa lâm sàng Tạp chí Y học Việt Nam. 2021;500(2).
3. Holmström B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (Clinical research ed). 2009;339:b3537.
4. Chavan PR, Chavan SV, Chavan NR, Trivedi VD. Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study. Journal of postgraduate medicine. 2009;55(1):17-21.
5. Nishida S, Kinoshita H, Mishima T, Kurokawa H, Sakaida N, Matsuda T. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging. International journal of urology: official journal of the Japanese Urological Association. 2011;18(9):653-8.
6. Popita C, Popita AR, Sitar-Taut A, Petrut B, Fetica B, Coman I. 1.5-Tesla Multiparametric-Magnetic Resonance Imaging for the detection of clinically significant prostate cancer. Clujul medical (1957). 2017;90(1):40-8.
7. Trương Thị Thanh, Hoàng Đình Âu. Giá trị của cộng hưởng từ trong chẩn đoán các nhân vùng chuyển tiếp tuyến tiền liệt theo PIRADS 2.1. Tạp chí Y học Việt Nam. 2023;522(2).
8. Lee H, Hwang SI, Lee HJ, Byun SS, Lee SE, Hong SK. Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone. PloS one. 2018; 13(6):e0199636.